ReviewHematology reports2026
Thrombotic Complications in Women Undergoing Assisted Reproductive Technologies: Pathophysiology, Prevention, and Clinical Management-A Narrative Review.
Review in Hematology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thrombotic complications represent uncommon but potentially life-threatening adverse events associated with assisted reproductive technologies (ARTs), particularly in the setting of controlled ovarian stimulation and ovarian hyperstimulation syndrome (OHSS). The relationship between thrombophilia, infertility, ovarian hyperstimulation syndrome (OHSS), and venous thromboembolism (VTE) remains complex and only partially understood. While antiphospholipid syndrome is a well-established acquired thrombophilic disorder associated with recurrent pregnancy loss, the association between common inherited thrombophilias and recurrent pregnancy loss is less consistent, and their contribution to primary infertility and implantation failure remains uncertain. Conversely, severe OHSS is consistently recognized as the principal treatment-related determinant of thrombotic events during IVF because of profound endothelial activation, hemoconcentration, and hypercoagulability. This narrative review summarizes the current evidence regarding the epidemiology, pathophysiology, and clinical presentation of thrombotic complications associated with assisted reproductive technologies, including deep vein thrombosis, pulmonary embolism, cerebral venous thrombosis, upper-extremity thrombosis, splanchnic vein thrombosis, and arterial thrombotic events. Current recommendations for thromboprophylaxis, diagnostic strategies, and therapeutic management are critically discussed, with particular attention to individualized risk assessment and the role of low-molecular-weight heparin in high-risk patients. Although routine thromboprophylaxis is not recommended for all women undergoing in vitro fertilization (IVF), careful evaluation of patient-specific thrombotic risk factors remains essential. Future prospective studies are needed to improve risk prediction, optimize preventive strategies, and establish evidence-based recommendations for women undergoing assisted reproduction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.